{"podcast":{"title":"Business News Today | 2 Min News | The Daily News Now!","slug":"business-finance-news-today-2-min-news-the-daily-news-now-7726192","podcast_index_feed_id":7726192,"rss_url":"https://feeds.fastcast.ai/the-daily-news-now-business.xml","website_url":"https://thednn.ai/","image_url":"https://image.fastcast.ai/cover/a77b5c94-431e-4490-8653-1f676f1da586.png","author":"The Daily News Now!","episode_count":2000,"summary":"Hosted by Corey with the Story, Business News Today is your daily source for the latest headlines and stories shaping the world of business, finance, and the global economy. From market trends and corporate earnings to startups, entrepreneurship, technology, real estate, consumer trends, and economic policy, we bring you the business news that matters most—in just a few minutes. Whether you're an entrepreneur, investor, executive, business owner, or simply someone who wants to stay informed, Business News Today delivers clear, concise updates to help you understand the forces shaping the economy and the future of business. Business News Today — Business news, all in one place. Powered by AI.","last_synced_at":"2026-09-17T06:21:31.382927+00:00","page_url":"https://stenobird.com/podcast/business-finance-news-today-2-min-news-the-daily-news-now-7726192"},"episode":{"title":"Cathie Wood Sees Value in Ionis Dip | Business and Finance News","slug":"cathie-wood-sees-value-in-ionis-dip-business-and-finance-news","published_at":"2026-07-18T15:01:18+00:00","page_url":"https://stenobird.com/podcast/business-finance-news-today-2-min-news-the-daily-news-now-7726192/cathie-wood-sees-value-in-ionis-dip-business-and-finance-news","show_page_url":"https://stenobird.com/podcast/business-finance-news-today-2-min-news-the-daily-news-now-7726192","url":"https://sources.thednn.ai/93a91af4807d9bac","audio_url":"https://api.fastcast.ai/audio/4b8addee-8a8b-4e85-8b17-4ead5974263b.mp3","summary":"Cathie Wood’s ARK Genomic Revolution ETF just dumped $15 million into Ionis Pharmaceuticals—right after the stock tanked 37% following a failed late-stage trial for its heart drug eplontersen. But here’s the twist: Ionis isn’t just betting on that one flop. They’ve got Tryngolza, a recently approved drug they’re now commercializing themselves—keeping bigger profits instead of licensing out. The pivot means more risk, but also higher rewards, as they slash prices to boost access and aim for cash flow break-even by 2028. With a solid pipeline including an FDA-reviewed drug for Alexander disease and pelacarsen in late-stage trials for stroke and heart attack prevention, Ionis’ RNA-targeted tech gives them a proven edge. Wood’s move? A bold, value-driven bet on Ionis’ long-term potential—despite the bumps ahead. Listen in comfort: Get a discount on a Soli Pillow: http://solipillow.com/discount/dnn. Advertise on DNN: advertise@thednn.ai This is an automated, high-level news summary based on public reporting. Report issues to feedback@thednn.ai. View sources & latest updates: https://sources.thednn.ai/93a91af4807d9bac","meta_description":"Cathie Wood’s ARK Genomic Revolution ETF just dumped $15 million into Ionis Pharmaceuticals—right after the stock tanked 37% following a failed late-stage…","key_points":[],"chapters":[],"topics":[],"duration_seconds":136,"processing_state":"not_requested","actions":[{"name":"request_transcript","method":"POST","url":"https://stenobird.com/v1/public/podcasts/business-finance-news-today-2-min-news-the-daily-news-now-7726192/episodes/cathie-wood-sees-value-in-ionis-dip-business-and-finance-news/transcription-requests","description":"Idempotently request low-priority transcript generation for this episode."},{"name":"read_markdown","method":"GET","url":"https://stenobird.com/podcast/business-finance-news-today-2-min-news-the-daily-news-now-7726192/cathie-wood-sees-value-in-ionis-dip-business-and-finance-news.md","description":"Read the agent-friendly Markdown representation of this episode resource."}]}}